Zacks Research began coverage on shares of Basilea Pharmaceutica (OTCMKTS:BPMUF – Free Report) in a report released on Monday,Zacks reports. The firm issued a hold rating on the stock.
Basilea Pharmaceutica Price Performance
Shares of Basilea Pharmaceutica stock opened at $84.00 on Monday. The company has a quick ratio of 5.97, a current ratio of 6.60 and a debt-to-equity ratio of 0.44. The stock’s fifty day moving average is $77.42 and its 200 day moving average is $70.11. Basilea Pharmaceutica has a one year low of $59.29 and a one year high of $84.00.
Basilea Pharmaceutica Company Profile
Recommended Stories
- Five stocks we like better than Basilea Pharmaceutica
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
